ArticleNature2025
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.Genes & development · 2026Review
- Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastases.bioRxiv : the preprint server for biology · 2026Article
- Article
- Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review).Oncology letters · 2026Review
- Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.Signal transduction and targeted therapy · 2026Article
- Tumor-derived PCSK9-enriched exosomes reprogram adipocytes to drive metabolic dysregulation and immune evasion in triple-negative breast cancer.Cell death & disease · 2026Article
- HOXC9 enhances cholesterol metabolism and malignancy in pancreatic ductal adenocarcinoma through ITGA10/FAK/PI3K/CREB-dependent HMGCR activation.Journal of gastroenterology · 2026Article
- Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology.Biomolecules · 2026Review
- PCSK9 and Breast Cancer Survival: A Mendelian Randomization Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Translating ferroptosis into oncology: challenges, opportunities and future directions.Nature reviews. Clinical oncology · 2026Review
- Self-fueling catalysis-driven membrane destabilization triggers CSC-enriched tumors ablation.Journal of nanobiotechnology · 2026Article
- Fibroblast-derived HSD11B1 deficiency drives lung cancer in never-smokers through steroid metabolic imbalance.NPJ precision oncology · 2026Article
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8Cell reports. Medicine · 2026Article
- ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer.Cancers · 2026Article
- Global surge in pancreatic cancer cases driven by ageing populations and modifiable risks.Journal of global health · 2026Article
- Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer.Molecular cancer · 2026Review
- Ferroptosis and metastasis: molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities.Molecular cancer · 2026Review
- Exploring metabolic dynamics of cancer metastasis through in vitro models.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Gilles RademakerDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.
Grace A HernandezDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.
Yurim SeoDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0002-1281-0919
Sumena DahalDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.
Lisa Miller-PhillipsHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Alexander L LiDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1233-0950
Xianlu Laura PengDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Changfei LuanDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Longhui QiuDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Maude A LiegeoisCardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
Bruce WangHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.ORCID 0000-0003-3486-5494
Kwun W WenDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Grace E KimDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4603-9448
Eric A CollissonFred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-8037-9388
Stephan F KrugerDepartment of Hematology/Oncology, LMU Klinikum, University of Munich Comprehensive Cancer Center, Munich, Germany.
Stefan BoeckDepartment of Hematology/Oncology, LMU Klinikum, University of Munich Comprehensive Cancer Center, Munich, Germany.ORCID 0000-0002-1922-2127
Steffen OrmannsInstitute of General Pathology, Medical University Innsbruck, Innsbruck, Austria.
Michael GuentherInstitute of General Pathology, Medical University Innsbruck, Innsbruck, Austria.
Volker HeinemannDepartment of Hematology/Oncology, LMU Klinikum, University of Munich Comprehensive Cancer Center, Munich, Germany.
Michael HaasDepartment of Hematology/Oncology, LMU Klinikum, University of Munich Comprehensive Cancer Center, Munich, Germany.
Mark R LooneyDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0241-9190
Jen Jen YehDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Roberto ZoncuDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.ORCID 0000-0003-1611-1891
Rushika M PereraDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA. rushika.perera@ucsf.edu.ORCID 0000-0003-2435-2273
Funding
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7MRestorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5MIdentifying Molecular Drivers of Cellular Plasticity in Pancreatic CancerR01CA240603 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERERA, RUSHIKA MIRIAM · 2020 to 2024
$1.8MDissecting new mechanisms of lysosome quality control in health and diseaseR01CA260249 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERERA, RUSHIKA MIRIAM · 2021 to 2025
$1.8MNCI NIH HHS R01 CA240603NCI NIH HHS R01 CA260249NIDDK NIH HHS P30 DK026743NIGMS NIH HHS T32 GM136547
Abstract
To grow at distant sites, metastatic cells must overcome major challenges posed by the unique cellular and metabolic composition of secondary organs
Indexed as
Carcinoma, Pancreatic DuctalNeoplasm MetastasisPancreatic NeoplasmsProprotein Convertase 9SterolsAnimalsCell Line, TumorCholesterolCholesterol, LDLFemaleHumansLiverLiver NeoplasmsLung NeoplasmsLysosomesMaleCholesterolCholesterol, LDLMechanistic Target of Rapamycin Complex 1PCSK9 protein, humanPcsk9 protein, mouseProprotein Convertase 9Sterols
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.